Table 4.

Category Variables in Responding and Nonresponding Patients

Variable Favorable Group Response Rate (%) Unfavorable Group Response Rate (%) P Value
Sex (M/F)* Female  38  Male  35  .93  
Karyotype (N/A)3-151 A  41  N  38  .81 
Pretreatment transfusions (yes/no)  no  53.3 yes  28.6  .09  
Pretreatment transfusions U/month <2  50  ≥2  21.7  .04  
Serum epo <500 U/L or ≥500 U/L  <500  48.3  ≥500  15.8  .02  
Serum epo <100 U/L or ≥100 U/L  <100  50  ≥100  29.4 .18 
Variable Favorable Group Response Rate (%) Unfavorable Group Response Rate (%) P Value
Sex (M/F)* Female  38  Male  35  .93  
Karyotype (N/A)3-151 A  41  N  38  .81 
Pretreatment transfusions (yes/no)  no  53.3 yes  28.6  .09  
Pretreatment transfusions U/month <2  50  ≥2  21.7  .04  
Serum epo <500 U/L or ≥500 U/L  <500  48.3  ≥500  15.8  .02  
Serum epo <100 U/L or ≥100 U/L  <100  50  ≥100  29.4 .18 

*Male/female.

F3-151

Normal karyotype/abnormal karyotype.

or Create an Account

Close Modal
Close Modal